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BACKGROUND
Uterine fibroids are a common cause of heavy menstrual bleeding and pain. Treat-
ment with the combination of relugolix (an oral gonadotropin-releasing hormone-
receptor antagonist), estradiol, and norethindrone acetate, administered once 
daily, may have efficacy in women with uterine fibroids and heavy bleeding while 
avoiding hypoestrogenic effects.
METHODS
We conducted two replicate international, double-blind, 24-week, phase 3 trials 
involving women with fibroid-associated heavy menstrual bleeding. Participants 
were randomly assigned in a 1:1:1 ratio to receive once-daily placebo, relugolix 
combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of noreth-
indrone acetate), or delayed relugolix combination therapy (40 mg of relugolix 
monotherapy, followed by relugolix combination therapy, each for 12 weeks). The 
primary efficacy end point in each trial was the percentage of participants with a 
response (volume of menstrual blood loss <80 ml and a ≥50% reduction in volume 
from baseline) in the relugolix combination therapy group, as compared with the 
placebo group. Key secondary end points were amenorrhea, volume of menstrual 
blood loss, distress from bleeding and pelvic discomfort, anemia, pain, fibroid 
volume, and uterine volume. Safety and bone mineral density were assessed.
RESULTS
A total of 388 women in trial L1 and 382 in trial L2 underwent randomization. A 
total of 73% of the participants in the relugolix combination therapy group in 
trial L1 and 71% of those in trial L2 had a response (primary end point), as com-
pared with 19% and 15%, respectively, of those in the placebo groups (P<0.001 for 
both comparisons). Both relugolix combination therapy groups had significant 
improvements, as compared with the placebo groups, in six of seven key secondary 
end points, including measures of menstrual blood loss (including amenorrhea), 
pain, distress from bleeding and pelvic discomfort, anemia, and uterine volume, 
but not fibroid volume. The incidence of adverse events was similar with relugolix 
combination therapy and placebo. Bone mineral density was similar with relugolix 
combination therapy and placebo but decreased with relugolix monotherapy.
CONCLUSIONS
Once-daily relugolix combination therapy resulted in a significant reduction in men-
strual bleeding, as compared with placebo, and preserved bone mineral density in 
women with uterine fibroids. (Funded by Myovant Sciences; LIBERTY 1 [L1] and LIB-
ERTY 2 [L2] ClinicalTrials.gov numbers, NCT03049735 and NCT03103087, respectively.)
A BS TR AC T
Treatment of Uterine Fibroid Symptoms 
with Relugolix Combination Therapy
Ayman Al-Hendy, M.D., Ph.D., Andrea S. Lukes, M.D., 
Alfred N. Poindexter III, M.D., Roberta Venturella, M.D., Ph.D., 
Claudio Villarroel, M.D., Hilary O.D. Critchley, M.D., Yulan Li, Ph.D., 
Laura McKain, M.D., Juan C. Arjona Ferreira, M.D., Andria G.M. Langenberg, M.D., 
Rachel B. Wagman, M.D., and Elizabeth A. Stewart, M.D. 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on April 22, 2021. For personal use only. No other uses without permission. 
 Copyright © 2021 Massachusetts Medical Society. All rights reserved. 
n engl j med 384;7 nejm.org February 18, 2021 631
Relugolix Treatment for Uterine Fibroid Symptoms
Uterine fibroids are common; the cumulative incidence by 50 years of age is approximately 70% among White women 
and 80% among Black women.1,2 Approximately 
25% of women with uterine fibroids have symp-
toms,3,4 most often heavy menstrual bleeding, 
which is often associated with anemia.5-7 Uterine 
fibroid–associated pain is the second most de-
bilitating problem.8-10
Although contraceptives are first-line medical 
treatments for uterine fibroid symptoms,11 the 
quality of evidence for their use is low.7,12 Inject-
able long-acting gonadotropin-releasing hormone 
(GnRH) agonists (e.g., leuprolide acetate) are ef-
fective; however, hypoestrogenic sequelae limit 
their duration of use or lead to the administra-
tion of additional hormonal therapy to mitigate 
side effects.5,13 The GnRH antagonist elagolix, 
administered with estradiol and norethindrone 
acetate, reduces heavy menstrual bleeding in 
women with uterine fibroids14 and is approved 
for the treatment of uterine fibroids for 24 
months.15 However, elagolix involves twice-daily 
administration because of its short half-life,16 
and its use has been associated with a loss of 
bone mineral density at 1 year and with adverse 
effects on blood pressure and levels of lipids and 
liver enzymes.15
The selective progesterone-receptor modula-
tor ulipristal acetate has been approved to treat 
uterine fibroids in some countries12,17; however, 
it has been linked to rare cases of serious liver 
injury, and the European Commission, on the 
basis of guidance from the European Medicines 
Agency, has recommended that ulipristal acetate 
for the treatment of uterine fibroids be used only 
in premenopausal women in whom surgical pro-
cedures (including uterine fibroid embolization) 
are not appropriate or have not worked.18 Surgery 
remains a common treatment option, although 
uterine-sparing procedures are associated with a 
substantial incidence of reoperation,19 and hyster-
ectomy (both with and without ovarian conserva-
tion) has long-term sequelae, including increased 
mortality and risk of cardiovascular disease.20-22 
With an estimated $34 billion in health care 
costs associated with fibroids in the United 
States alone,22 there is a major need for a non-
surgical long-term treatment option,7 particu-
larly one that addresses women’s usual prefer-
ence for uterine-sparing alternatives regardless 
of their reproductive plans.4
Relugolix is an orally active nonpeptide GnRH-
receptor antagonist that is suitable for daily use. 
It competitively binds to pituitary GnRH recep-
tors, blocking the binding and signaling of en-
dogenous GnRH23 and thus leading to reversible, 
dose-dependent decreases in gonadotropin con-
centrations and subsequent suppression of ovar-
ian estradiol and progesterone production. In pre-
vious phase 3 trials involving Japanese women 
with symptomatic fibroids, relugolix at a dose of 
40 mg led to improvements similar to those 
observed with leuprolide acetate with regard to 
heavy menstrual bleeding, anemia, and pain24 
and to a significant reduction in pain as com-
pared with placebo.25 To achieve efficacy, mini-
mize hypoestrogenic side effects, and preserve 
bone mineral density, relugolix combination ther-
apy (consisting of 40 mg of relugolix, 1 mg of 
estradiol, and 0.5 mg of norethindrone acetate) 
was developed as a once-daily treatment for 
maintaining estradiol levels within the physio-
logic range of the early follicular phase of the 
menstrual cycle,26,27 with the addition of a pro-
gestin to mitigate the unopposed estrogen ac-
tion that could lead to endometrial hyperplasia.28
We report the results of two replicate interna-
tional, double-blind, randomized, placebo-con-
trolled, phase 3 trials (LIBERTY 1 and LIBERTY 2) 
in which we assessed the efficacy and safety 
of once-daily relugolix combination therapy in 
women with fibroid-associated heavy menstrual 
bleeding. We also evaluated a delayed relugolix 
combination therapy regimen, which consisted 
of relugolix monotherapy for 12 weeks followed 
by 12 weeks of relugolix combination therapy, in 
an additional group of participants to assess the 




In these two trials, we enrolled women in Africa, 
Europe, North America, and South America. 
LIBERTY 1 (trial L1) was conducted at 80 sites, 
and LIBERTY 2 (trial L2) at 99 sites. Premeno-
pausal women 18 to 50 years of age who had a 
diagnosis of fibroids as confirmed on ultraso-
nography and who had heavy menstrual bleed-
ing, as assessed by the alkaline hematin meth-
od,29 were eligible. The alkaline hematin method 
directly measures the volume of menstrual blood 
loss by comparing hematin from menstrual 
products against calibration curves created from 
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a simultaneous venous blood sample.29 Heavy 
menstrual bleeding was defined as a volume of 
menstrual blood loss of 80 ml or more per cycle 
for two cycles or a volume of 160 ml or more 
during one cycle.
Patients were excluded from the trials if they 
had a z score of less than −2.0 for bone mineral 
density at the lumbar spine, total hip, or femoral 
neck; had other causes of heavy menstrual 
bleeding30; or were using hormonal therapy. Ad-
ditional exclusion criteria are summarized in 
Table S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org.
Trial Design and Oversight
Participants were randomly assigned, in a 1:1:1 
ratio, by means of an interactive website to re-
ceive blinded placebo for 24 weeks, relugolix 
combination therapy for 24 weeks, or delayed 
relugolix combination therapy (relugolix mono-
therapy, followed by relugolix combination ther-
apy, each for 12 weeks) (Fig. S3). A 40-mg relu-
golix tablet and a capsule containing estradiol 
and norethindrone acetate, or a placebo tablet 
and capsule, were packaged together in blister 
cards for once-daily coadministration. The de-
layed relugolix combination therapy group re-
ceived the 40-mg relugolix tablet and a placebo 
capsule for 12 weeks, followed by the active-
agent tablet and capsule for 12 weeks. The de-
layed relugolix combination therapy group was 
included to allow for the comparison of bone 
mineral density and vasomotor symptoms in the 
combination and monotherapy groups during the 
first 12 weeks of the trial. Trial visits occurred 
at baseline and every 4 weeks for 24 weeks.
The trials were conducted in accordance with 
the guidelines of the International Council for 
Harmonisation and the principles of the Decla-
ration of Helsinki. All the participants provided 
written informed consent. The sponsor, Myovant 
Sciences, designed the trials and analyzed the 
data; the investigators and the sponsor jointly 
conducted the trials and collected the data. A 
steering committee of academic gynecologists 
provided strategic and scientific guidance. A data 
and safety monitoring committee that comprised 
practicing gynecologists and a statistician moni-
tored trial progress and reviewed safety data. The 
seventh author was responsible for data analysis 
and vouches for the accuracy of the data. The 
sponsor held the data, and the authors had full 
access to the data analyses, reviewed the analy-
ses, and vouch for fidelity of the trial to the 
protocol, available at NEJM.org. The first draft 
of the manuscript was written by the penultimate 
author. The other authors critically reviewed 
and provided feedback on the first draft and 
subsequent versions. A medical writer, who was 
funded by the sponsor, assisted with the prepa-
ration of the manuscript and its submission for 
publication.
Efficacy End Points
In the primary efficacy analysis in each trial, a 
response was defined as both a volume of men-
strual blood loss of less than 80 ml and a reduc-
tion of at least 50% from the baseline volume of 
menstrual blood loss, as measured by the alka-
line hematin method, over the last 35 days of the 
treatment period. The primary comparison was 
the percentage of participants who had a re-
sponse to relugolix combination therapy, as com-
pared with placebo.
Key secondary end points at week 24 included 
the following: the percentage of women who 
reported amenorrhea; the mean percent reduc-
tion in the volume of menstrual blood loss; re-
duction in distress related to bleeding, the pass-
ing of blood clots, and tightness or pressure in 
the pelvic area, as measured by the Bleeding 
and Pelvic Discomfort scale31; the percentage of 
women with a baseline hemoglobin level of no 
more than 10.5 g per deciliter who had an in-
crease of more than 2 g per deciliter; the per-
centage of women with moderate-to-severe pain 
at baseline (numerical rating scale score of ≥4, 
on a scale from 0 [no pain] to 10 [worst imagin-
able pain]) who had minimal-to-no fibroid-asso-
ciated pain according to the numerical rating 
scale score in a daily electronic diary; the per-
cent change in the volume of the largest fibroid; 
and the percent change in uterine volume. (The 
last two end points were assessed by means of 
transvaginal ultrasonography.) Details about each 
end point are provided in Table S2.
Safety Assessments
Safety evaluations included the monitoring of 
vital signs, physical examination, adverse events, 
clinical laboratory variables, and 12-lead electro-
cardiography. Changes in bone mineral density 
were assessed by means of dual-energy x-ray 
absorptiometry at baseline and every 3 months 
during the trials. Endometrial biopsies were per-
formed at baseline and at week 24 or the end of 
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the treatment period (i.e., after the participant’s 
last dose of relugolix combination therapy or 
placebo).
Statistical Analysis
We calculated that the enrollment of approxi-
mately 390 participants in each trial would pro-
vide each trial with more than 90% power to 
detect a difference of at least 30 percentage 
points in the primary end point, at a two-sided 
alpha level of 0.05, between the relugolix combi-
nation therapy groups and placebo groups, as-
suming that 25% of the participants in the pla-
cebo group would have a response and that 20% 
of the participants would withdraw. Efficacy and 
safety analyses were performed in the modified 
intention-to-treat population, which included all 
the participants who underwent randomization 
and received at least one dose of relugolix (as 
combination therapy or monotherapy) or placebo.
The comparison of the primary end point 
between relugolix combination therapy and pla-
cebo was analyzed with the use of a Cochran–
Mantel–Haenszel test for proportions, with strati-
fication according to the baseline mean volume 
of menstrual blood loss (<225 ml vs. ≥225 ml) 
and geographic region (North America vs. rest 
of world). Rules for the handling of missing data 
were implemented for deriving the response sta-
tus at week 24 or the end of the treatment period 
(last 35 days of the treatment period), with con-
sideration for the duration of exposure to treat-
ment or placebo and for adherence to the collec-
tion of menstrual products against entries in the 
electronic diary (i.e., the number of days with 
returned menstrual products, divided by the num-
ber of days with reported bleeding and product 
use, according to the data recorded in the elec-
tronic diary). In participants with 100% adher-
ence, response status was based on the observed 
volume of menstrual blood loss. Participants who 
reported amenorrhea or “spotting or negligible 
bleeding,” as confirmed by data collected in the 
electronic diary, were considered to have had a 
response. Participants who received treatment or 
placebo for less than 4 weeks or who withdrew 
to undergo surgical intervention for uterine fi-
broids were considered not to have had a re-
sponse. Detailed rules regarding the handling of 
missing data were prespecified (Table S3).
Analyses of the primary and key secondary 
efficacy end points were performed at an overall 
alpha level of 0.05 (two-sided) for the compari-
son of relugolix combination therapy with pla-
cebo. A gate-keeping, mixed-sequence testing 
procedure was used to maintain the familywise 
type I error. In each trial, the primary end point 
was tested first; if the P value was less than 0.05, 
the key secondary efficacy end points were 
tested as prespecified in the statistical analysis 
plans. In trial L1, the first four key secondary 
end points were tested sequentially in the order 
listed (see above), and the remaining three sec-
ondary end points were to be tested with the use 
of the Hochberg step-up procedure (Fig. S1). In 
trial L2, the first, second, third, and fifth sec-
ondary end points were tested sequentially, fol-
lowed by testing of the other three key second-
ary end points (fourth, sixth, and seventh) with 
the use of the Hochberg procedure (Fig. S2). (This 
change in the order of hierarchical testing was 
made on the basis of the results of trial L1 before 
unblinding and the analysis of data in trial L2.)
Efficacy analyses comparing the delayed relu-
golix combination therapy groups with the pla-
cebo groups were not prespecified for any end 
points other than the percentage of participants 
with a response regarding menstrual blood loss 
(which was not included among the key second-
ary end points in the gatekeeping statistical test-
ing procedure that was adjusted for multiplicity). 
Thus, data from the delayed relugolix combina-
tion therapy groups regarding the secondary end 
points are considered to be supportive.
R esult s
Participants
From April 2017 through October 2018, a total 
of 388 women underwent randomization in trial 
L1; from June 2017 through December 2018, a 
total of 382 women underwent randomization in 
trial L2. A total of 308 women (79%) in trial L1 
and 302 women (79%) in trial L2 completed the 
trial regimen. The percentages of participants 
who completed the trial were similar across all 
the trial groups (77 to 82%) (Fig. S4). Within 
each trial, the demographic and clinical charac-
teristics of the participants at baseline were 
similar across the trial groups (Tables 1 and S4).
Primary Efficacy End Point
In the relugolix combination therapy groups, 
73% of the participants in trial L1 and 71% of 
those in trial L2 had a response, as compared 
with 19% and 15%, respectively, of the partici-
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pants in the placebo groups (P<0.001 for both 
comparisons) (Fig. 1). In each trial, the observed 
treatment effects appeared to be similar, regard-
less of race or other characteristics of the par-
ticipants at baseline (Fig. S5). In the delayed 
relugolix combination therapy groups, the per-
centages of participants with a response were 
similar in the two trials: 80% in trial L1 and 
73% in trial L2.
Key Secondary Efficacy End Points
Relugolix combination therapy was superior to 
placebo with regard to six of seven key second-
ary end points that were tested hierarchically in 
trial L1 and trial L2 (Table 2). Amenorrhea over 
the last 35 days of the treatment period occurred 
in 52% and 50% of the participants receiving 
relugolix combination therapy in trials L1 and 
L2, respectively, as compared with 6% and 3%, 
respectively, of those receiving placebo (P<0.001 
for both comparisons).
The mean reduction in menstrual blood loss 
from baseline to week 24 in the relugolix com-
bination therapy groups was 84.3% in both trial 
L1 and trial L2, as compared with 23.2% and 
15.1%, respectively, in the placebo groups (P<0.001 
for both comparisons). Reduction in blood loss 
occurred by week 4 and was sustained through 
week 24 (Fig. S6). In both trials, scores on the 
Bleeding and Pelvic Discomfort scale improved 
significantly from baseline in the relugolix com-
bination groups, as compared with those in the 
placebo groups (Fig. S6), and more than 50% of 
the participants who had anemia at baseline had 
an increase of more than 2 g per deciliter in 
hemoglobin levels with relugolix combination 
therapy, as compared with placebo.
In addition, among the approximately 50% of 
the participants with moderate-to-severe pain at 
baseline who met the trial pain-evaluation re-
quirements, the percentages of participants who 
had reductions to minimal or no pain (maxi-
mum numerical rating scale score, ≤1) over the 
last 35 days of the treatment period were sig-
nificantly greater in the relugolix combination 
therapy groups than in the placebo groups (43% 
in trial L1 and 47% in trial L2 vs. 10% in trial L1 
and 17% in trial L2; P<0.001 for both compari-
sons) (Fig. S6).
The overall uterine volume was decreased to a 
greater extent with relugolix combination therapy 
than with placebo (P<0.001). However, changes 
Figure 1. Participants with Reduction in Heavy Menstrual Bleeding.
Shown are the percentages of women who had a response, which was defined as a volume of menstrual blood loss 
of less than 80 ml and a reduction of at least 50% from the baseline volume of menstrual blood loss, as measured 
by the alkaline hematin method, over the last 35 days of the treatment period. The primary end-point analysis in each 
trial was the comparison of relugolix combination therapy with placebo. CI denotes confidence interval, L1 LIBERTY 1, 
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in the volume of the largest fibroid with relugo-
lix combination therapy did not differ signifi-
cantly from those with placebo (Table 2). Addi-
tional secondary end points, which were not 
tested hierarchically, are reported in Table S5.
Safety
In trial L1, the overall incidence of adverse 
events was 66% in the placebo group, 62% in the 
relugolix combination therapy group, and 73% 
in the delayed relugolix combination therapy 
group; in trial L2, the incidence was 59%, 60%, 
and 71%, respectively (Table 3). Serious adverse 
events were reported infrequently; each serious 
adverse event that was reported occurred in one 
participant in a given trial group (Table S6). No 
deaths were reported.
Hot flash was the most frequently reported 
adverse event in both trials. In trial L1, hot flash 
occurred in 8% of the participants in the placebo 
group, in 11% of those in the relugolix combina-
tion therapy group, and in 36% of those in the 
delayed relugolix combination therapy group; in 
trial L2, the incidence was 4%, 6%, and 35%, 
respectively.
In trial L1, hypertension as an adverse event 
was reported in no participants in the placebo 
group, in 5% of the participants in the relugolix 
combination therapy group, and in 2% of those 
in the delayed relugolix combination therapy 
group. In trial L2, the incidence was 3%, 4%, 
and 6%, respectively. Data regarding partici-
pants with a history of hypertension are report-
ed in Table S4.
The percent changes from baseline to weeks 
12 and 24 in bone mineral density at the lumbar 
spine (L1 through L4) and the total hip were 
similar in the relugolix combination therapy 
group and the placebo group in both trials 
(Fig. 2A and 2B and Table S7). As expected, in 
the delayed relugolix combination therapy group, 
the bone mineral density at the lumbar spine 
and the total hip decreased from baseline at 
week 12 with relugolix monotherapy, which was 
followed by a plateau after the initiation of relu-
golix combination therapy (Fig. 2A and 2B).
Laboratory tests and vital signs, including sys-
tolic and diastolic blood pressures, were similar 
among the groups. There were no meaningful 
differences in the mean changes from baseline 
or in the percentages of participants who met 
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including liver-function tests and lipid levels 
(Tables S8 and S9).
At week 24, no cases of endometrial hyper-
plasia or endometrial cancer had occurred in the 
relugolix groups (i.e., the relugolix combination 
therapy group and the delayed relugolix combi-
nation therapy group). Endometrial hyperplasia 
without atypia was observed in two participants in 
Figure 2. Change in Bone Mineral Density.
Least-squares means were based on mixed-effects models with baseline volume of menstrual blood loss, geographic region, age at 
baseline, body-mass index at baseline, bone mineral density at baseline, race, visit, and trial group–by–visit interaction as fixed effects. 
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the placebo group in trial L1. No pregnancies were 
reported in the relugolix groups in either trial.
Discussion
In these two randomized, placebo-controlled, 
phase 3 trials involving women with symptom-
atic uterine fibroids, the percentage of partici-
pants with a response (i.e., volume of menstrual 
blood loss of <80 ml and a ≥50% reduction in 
volume from baseline) was significantly higher 
with relugolix combination therapy than with 
placebo. In addition, benefits were observed 
with relugolix combination therapy for six of 
seven key secondary end points, including amen-
orrhea in half the participants; an average (least-
squares mean) 84.3% reduction in menstrual 
blood loss, with the decrease first observed at 
4 weeks and persisting through 24 weeks; an 
improvement in hemoglobin levels in partici-
pants with anemia; and pain reduction in those 
with moderate-to-severe pain at baseline.
The trial population was representative of 
women with symptomatic fibroids in the gen-
eral population.5,8,13,32 Approximately half the 
women were Black. Overall, the mean body-
mass index (the weight in kilograms divided by 
the square of the height in meters) of the par-
ticipants was in the obese range (≥30.0), and the 
mean volume of menstrual blood loss (218.8 to 
239.4 ml across groups in trial L1 and 211.8 to 
246.7 ml across groups in trial L2) was almost 
3 times the upper limit of what has historically 
been considered the normal range. The majority 
of women had moderate-to-severe uterine fibroid–
associated pain, and most experienced marked 
distress because of their symptoms and substan-
tially impaired quality of life. The treatment ef-
fect of relugolix combination therapy on reducing 
menstrual bleeding was consistent, regardless of 
race or other characteristics of the participants 
or fibroids.
Pain is common in women with uterine fi-
broids, and the distress that women experience 
from bleeding and pain is underappreciated.33 
Yet the effects of treatment on fibroid-associated 
pain are infrequently assessed in clinical trials. 
The LIBERTY phase 3 trials showed a reduction 
in rigorously assessed fibroid-associated pain 
with the use of a daily electronic diary and a 
validated pain-outcome measure, a finding that 
is supported by a 12-week, phase 3 trial of relu-
golix monotherapy.25 Participants in our two trials 
described considerable discomfort and distress 
associated with their fibroids at baseline, with 
those in the relugolix combination therapy group 
reporting significantly less distress from bleed-
ing, passing of blood clots, and tightness or pres-
sure in the pelvic area at the end of the treat-
ment period than those who received placebo. 
There was no significant reduction in the vol-
ume of the largest fibroid, but the reduction in 
uterine volume, as measured by means of ultra-
sonography, suggests a reduced fibroid burden. 
The incidence of serious adverse events and non-
serious adverse events was similar overall in the 
relugolix combination therapy groups and the 
placebo groups.
Fibroid growth and extracellular matrix pro-
duction are stimulated by estrogen and proges-
terone by means of paracrine mechanisms.34 
Although a potential direct antiproliferation ef-
fect of GnRH antagonists against human fibroid 
cells has been reported,35 a recent review of medi-
cal management of uterine fibroids suggests 
that the direct effect on fibroids of GnRH-recep-
tor agonists and antagonists is probably modest 
at best.36 The estrogen-threshold hypothesis pro-
poses that maintenance of the estradiol concen-
tration between 20 and 50 pg per milliliter (70 and 
180 pmol per liter) can decrease fibroid growth 
while minimizing hypoestrogenic adverse ef-
fects.26 In a phase 1 study, the median trough 
concentrations of estradiol were consistently less 
than 10 pg per milliliter (40 pmol per liter) with 
the administration of 40 mg of relugolix alone 
for 6 weeks but remained above 20 pg per milli-
liter when relugolix was coadministered with 1 mg 
of estradiol and 0.5 mg of norethindrone acetate.37
The inclusion of the delayed relugolix combi-
nation therapy group in the LIBERTY trials al-
lowed for the comparison of the effects of com-
bination therapy with monotherapy. We found 
that 12 weeks of monotherapy resulted in a loss 
of bone mineral density and a higher incidence 
of vasomotor adverse events, as compared with 
relugolix combination therapy, and although the 
transition to relugolix combination therapy pre-
vented further loss of bone mineral density, it did 
not reverse the changes in bone mass. The ini-
tiation of treatment with relugolix combination 
therapy, as compared with relugolix monother-
apy (followed later by relugolix combination 
therapy), did not meaningfully affect efficacy 
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with respect to the volume of menstrual blood 
loss. The present trials showed that relugolix 
combination therapy reduced menstrual bleed-
ing and fibroid-associated pain to a greater ex-
tent than placebo, without substantive hypoes-
trogenic effects, over a period of 6 months.
These trials had limitations. Many women 
with self-reported heavy menstrual bleeding and 
uterine fibroids did not pass screening owing to 
strict assessment criteria, which is a situation 
that could limit generalizability, and the dura-
tion of the trial regimen was only 6 months. 
Participants who completed these trials were 
offered enrollment in a 28-week extension study 
with open-label relugolix combination therapy and 
a subsequent 52-week randomized-withdrawal 
trial; these studies may provide more informa-
tion regarding the long-term benefits and risks 
of relugolix therapy.
In these trials, once-daily relugolix combina-
tion therapy resulted in a substantial reduction 
in heavy menstrual bleeding in women with 
uterine fibroids, with resolution of anemia, a 
reduction in pain, and reduced distress related 
to bleeding and pelvic discomfort, while preserv-
ing bone density and minimizing the incidence 
of hot flashes associated with relugolix mono-
therapy.
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